January 2022

Pregnant women undergoing unnecessary invasive procedures

Posted: 31/01/2022 9:27:38 AM
GeneSyte is a non-invasive genetic prenatal screening test which can be done as early as 10 weeks or at any time throughout pregnancy.  It takes a sample of the mothers blood which contains the baby’s DNA and can accurately detect chromosomal changes in the baby during pregnancy.
 
A recent study of 1,000 pregnant women demonstrated the accuracy of GeneSyte  by identify that 42 women would have been incorrectly classified as high risk and referred for CVS (Chorionic Villus Sampling) or Amniocentesis where only 5 pregnant women actually needed such invasive diagnostic testing.

GeneSyte is a simple blood test that can offer you piece of mind. Download a referal form
 

Media Contact

Meline Walton
Media & Communications Manager
M: +61 452 433 369
E: meline.walton@genea.com.au

About Genea

Genea is one of Australia’s leading providers for infertility, IVF and other assisted conception treatment with 31 years of experience in the field. The company has long been a fertility pioneer, with research and technologies developed in-house virtually doubling IVF success rates in the mid-nineties and continuing to improve outcomes today. In September 2017, Genea was listed in the Australian Financial Review’s Top 50 Most Innovative Companies List, ranking number 25.